Shorter-term Herceptin Sufficient? No Agreement Shorter-term Herceptin Sufficient? No Agreement
Different conclusions have been drawn from similar findings, perhaps as a result of subjective margins for equivalence in HER2+ breast cancer research.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 14, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Can T-DM1 Match Chemotherapy Plus Dual Blockade in HER2+ Breast Cancer?
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
FDA Approves Amgen And Allergan's KANJINTI ™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin
Third FDA Approval From Amgen's Biosimilars Portfolio
THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
"The FDA approval...
Source: Amgen News Release - June 13, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin
THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Kanjinti (trastuzumab-anns) for all approved indications of the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 13, 2019 Category: Drugs & Pharmacology Source Type: news
Herzuma (Trastuzumab-pkrb for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 30, 2019 Category: Drugs & Pharmacology Source Type: news
Promising Results With Trastuzumab Deruxtecan in Early HER2+ Breast Cancer
Researchers tested a novel antibody-drug conjugate known as trastuzumab deruxtecan in an expansion cohort of a phase I study of patients with advanced HER2+ breast cancer previously treated with trastuzumab emtansine. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Pivotal phase 2 DESTINY-Breast01 trial met primary endpoint, supporting global regulatory submission plan to start in first half of fiscal year 2019
TOKYO and MUNICH and BASKING RIDGE, N.J., May 8, 2019 -- (Healthcare Sales & Marketing Network) -- Daii... Biopharmaceuticals, Oncology Daiichi Sankyo, AstraZeneca, trastuzumab deruxtecan, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 8, 2019 Category: Pharmaceuticals Source Type: news
Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine. (Source: World Pharma News)
Source: World Pharma News - May 8, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Roche's Kadcyla nabs adjuvant treatment indication
The data found that Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 7, 2019 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the US Food and Drug Administration (FDA) has approved Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) who have residual invasive disease after neoadjuvant (before surgery) taxane and Herceptin® (trastuzumab)-based treatment. (Source: Roche Media News)
Source: Roche Media News - May 6, 2019 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the US Food and Drug Administration (FDA) has approved Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) who have residual invasive disease after neoadjuvant (before surgery) taxane and Herceptin® (trastuzumab)-based treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - May 6, 2019 Category: Pharmaceuticals Source Type: news
Long-Term Results Confirm Subcutaneous Trastuzumab ’s Efficacy in HER2+ Breast Cancer
The long-term results of the phase III HannaH trial confirmed the similarity between the subcutaneous and intravenous formulation of trastuzumab in patients with HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 6, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer
South San Francisco, CA -- May 3, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine) for adjuvant (after... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 3, 2019 Category: Drugs & Pharmacology Source Type: news
De-Escalating Treatment in Metastatic HER2+ Breast Cancer: Is it Safe?
Researchers tested omitting chemotherapy from a treatment regimen involving dual blockade with pertuzumab and trastuzumab in patients with metastatic HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 1, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Sandoz nabs rights to Herceptin biosim
The division of Novartis has made a deal with Taiwan ' s EirGenix, which will be responsible for development and manufacturing of the med (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 30, 2019 Category: Pharmaceuticals Source Type: news
